Yifeng Pharmacy Chain Co., Ltd. (603939.SS) Bundle
Who is buying into Yifeng Pharmacy Chain Co., Ltd. (603939.SS) and why it matters: retail investors control about 24% of shares while private companies hold roughly 23%, institutions account for ~17.69% and insiders sit on 11.85%, with three major backers-Ningbo Meishan Free Trade Zone Jikang (LP) at 22%, Capital Today at 19% and Chairman Gao Yi at 12%-combining for a commanding 52% stake that shapes corporate strategy; institutional exposure is modest (77 institutions holding 19,907,329 shares or 1.64% as of Nov 25, 2025, totaling about $70,132 in value, an average allocation of 0.138% and roughly 258,000 shares each, with the number of institutions down 3.75% last quarter), while market metrics-market cap ~CNY 27.06 billion, trailing P/E 17.05, forward P/E 14.50, beta 0.494 and a ~1.6% dividend yield-combine with Yifeng's vast store network and brand recognition to influence investor sentiment and strategies; read on to unpack how these figures translate into power, risk and opportunity for current and potential shareholders.
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Who Invests in Yifeng Pharmacy Chain Co., Ltd. and Why?
Yifeng Pharmacy Chain's shareholder base is diversified across retail, private, institutional, and insider holders, with several large strategic stakes shaping governance and strategy. Key ownership stats:- Retail investors: ~24%
- Private companies: ~23%
- Institutional investors: ~17.69%
- Insiders (executives & board): ~11.85%
- Largest single holder - Ningbo Meishan FTZ Jikang Enterprise Management Partnership (LP): ~22%
- 2nd & 3rd largest - Capital Today: ~19%; Gao Yi: ~12% (Gao Yi is Chairman)
| Holder Type / Name | Approx. Stake | Typical Motive |
|---|---|---|
| Retail Investors (aggregate) | 24% | Speculation on growth, dividend yield, consumer-sector exposure |
| Private Companies (strategic/industrial) | 23% | Sector synergies, supply-chain integration, strategic positioning |
| Institutional Investors (mutual funds, asset managers) | 17.69% | Portfolio diversification, long-term return prospects, corporate governance influence |
| Insiders (management & board) | 11.85% | Alignment of incentives, control over strategy, signaling confidence |
| Ningbo Meishan FTZ Jikang (LP) - largest single holder | 22% | Large strategic/financial stake enabling influence on major decisions |
| Capital Today | 19% | Private equity / strategic investment for value creation |
| Gao Yi (Chairman) | 12% | Leadership stake tying executive incentives to shareholder value |
- Retail investors: attracted by brand recognition, pharmacy network scale, cash flow potential and retail liquidity; their ~24% stake means public sentiment can materially affect market performance.
- Private companies: with ~23% collectively, these investors may seek operational synergies (distribution, procurement), M&A optionality, or defensive strategic positions in the pharma retail channel.
- Institutional investors: holding ~17.69%, they provide validation of Yifeng's financial profile, often driving improved governance and demanding transparency and steady returns.
- Insiders: ~11.85% ownership aligns management incentives with shareholders and reduces agency risk, while enabling the board to pursue longer-term strategies.
- Large cornerstone shareholders (Ningbo Meishan FTZ Jikang, Capital Today, Gao Yi): their combined concentrated stakes (>50% when aggregated with other major holders) create a governance dynamic where strategic decisions, board composition, and major transactions can be heavily influenced by a few parties.
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) Institutional Ownership and Major Shareholders of Yifeng Pharmacy Chain Co., Ltd. (603939.SS)
Yifeng Pharmacy Chain's institutional profile shows concentrated but modest engagement: 77 institutional investors collectively hold 19,907,329 shares (1.64% of outstanding shares) with a total value of approximately $70,132 USD. The investor base is small and slightly contracting, and the average institutional position is limited both in share count and portfolio weight.- Institutional investors: 77 (total shares held: 19,907,329)
- Institutional ownership as % of outstanding: 1.64%
- Total value of institutional holdings: ≈ $70,132 USD
- Average institutional allocation to Yifeng Pharmacy Chain: 0.138% of portfolios
- Average shares held per institution: ≈ 258,000 shares
- Change in number of institutional investors (most recent quarter): -3.75%
| Metric | Value |
|---|---|
| Total institutional holders | 77 |
| Total institutional shares | 19,907,329 |
| Institutional ownership (% of outstanding) | 1.64% |
| Estimated company outstanding shares | ≈ 1,213,536,952 |
| Total value of institutional holdings (USD) | ≈ $70,132 |
| Average portfolio allocation (per institution) | 0.138% |
| Average shares per institution | ≈ 258,000 |
| Quarterly change in number of institutions | -3.75% |
Major institutional shareholders (selected)
- Bridge Builder International Equity Fund (BBIEX) - largest institutional holder
- Fidelity Series Emerging Markets Opportunities Fund (FEMSX) - second largest
- Mercer Emerging Markets Equity Fund Class I (MEMSX) - third largest
| Institution | Estimated shares held | % of institutional holdings | % of outstanding shares |
|---|---|---|---|
| Bridge Builder International Equity Fund (BBIEX) | 5,500,000 | 27.64% | 0.453% |
| Fidelity Series Emerging Markets Opportunities Fund (FEMSX) | 3,200,000 | 16.08% | 0.264% |
| Mercer Emerging Markets Equity Fund Class I (MEMSX) | 2,000,000 | 10.05% | 0.165% |
| Other institutional holders (aggregate) | 9,207,329 | 46.23% | 0.758% |
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) Key Investors and Their Impact on Yifeng Pharmacy Chain Co., Ltd. (603939.SS)
Ningbo Meishan Free Trade Zone Jikang Enterprise Management Partnership (LP), Capital Today and Chairman Gao Yi together hold a controlling block that materially shapes Yifeng Pharmacy Chain Co., Ltd.'s strategic trajectory, governance and capital allocation. The top three shareholders control 52% of shares (22% + 19% + 12%), creating concentrated ownership that both stabilizes leadership and magnifies the influence of major stakeholders on board composition, M&A appetite, dividend policy and long-term investments.- Ningbo Meishan Free Trade Zone Jikang Enterprise Management Partnership (LP) - 22%: large institutional LP capable of steering major corporate decisions and influencing strategic partnerships and capital structure choices.
- Capital Today - 19%: significant strategic investor likely to provide financial support, strategic guidance and access to broader capital markets or co-investment opportunities.
- Gao Yi (Chairman) - 12%: insider ownership aligning executive incentives with shareholder value and enabling direct influence on corporate governance and board-level decisions.
- Combined top-three ownership - 52%: concentrated control that can deliver cohesive strategy execution but may also limit minority shareholder influence.
- Insider alignment: meaningful insider stake (chairman + management) tends to reduce agency conflict and encourage long-term performance focus.
- Signaling effect: presence of these major, stable investors can attract further institutional capital seeking governance stability.
| Investor | Stake (%) | Representative Role / Influence |
|---|---|---|
| Ningbo Meishan Free Trade Zone Jikang Enterprise Management Partnership (LP) | 22 | Major LP investor with capacity to influence strategic decisions, capital allocation and large transactions |
| Capital Today | 19 | Strategic institutional investor providing financial backing and potential strategic partnerships |
| Gao Yi (Chairman) | 12 | Insider leadership with direct board influence and aligned executive incentives |
| Top 3 Combined | 52 | Concentrated control - decisive in governance, strategy and capital decisions |
- Implications for capital markets: with a 52% block held by the top three, liquidity of free float is lower, which may amplify price movements for material corporate events (earnings surprises, M&A, board changes).
- Governance dynamics: strong insider and institutional stakes increase likelihood of long-term strategic planning, but also raise the importance of minority protection and transparent disclosure.
- Strategic levers: these shareholders can expedite expansion (store rollouts, supply chain investments), approve or reject major acquisitions, and set dividend or buyback policies that affect ROE and shareholder returns.
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) - Market Impact and Investor Sentiment
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) occupies a significant position in China's pharmaceutical retail landscape. Its market capitalization of approximately CNY 27.06 billion, combined with a trailing P/E of 17.05 and a forward P/E of 14.50, frames the company as a moderately valued, potentially growth-oriented name. The company's low beta (0.494) points to lower volatility relative to broad-market benchmarks, while a dividend yield near 1.6% adds an income component that complements total-return strategies.| Metric | Value | Implication |
|---|---|---|
| Market Capitalization | CNY 27.06 billion | Material scale in retail pharmacy sector; institutional visibility |
| Trailing P/E | 17.05 | Moderate valuation relative to recent earnings |
| Forward P/E | 14.50 | Market expects earnings growth; valuation compression opportunity |
| Beta | 0.494 | Lower volatility-suits defensive allocations |
| Dividend Yield | ~1.6% | Modest income for income-focused investors |
| Retail Footprint & Brand | Extensive store network; strong brand recognition | Revenue stability, local market trust, cross-selling potential |
- Institutional investors: attracted by stable cash flows, predictable margins, and the large market cap that supports sizeable allocations.
- Growth-oriented investors: drawn by forward P/E of 14.50 signaling expected earnings acceleration versus current valuation.
- Risk-averse investors: favor the low beta (0.494) for portfolio diversification into defensive consumer-health exposure.
- Income-focused investors: consider the ~1.6% dividend yield as a supplementary income source, especially combined with dividend growth potential.
- Strategic/sector investors: value the store network and brand for market share expansion, omnichannel rollout, and healthcare service integration.
Yifeng Pharmacy Chain Co., Ltd. (603939.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.